Liquidia Corporation (NasdaqCM: LQDA)
Health Care · Pharmaceuticals · US
$70.96
+0.98% today · +167.7% 1Y
Liquidia Corporation (NasdaqCM: LQDA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.29B and employs 216 people.
Over the last twelve months the share price has gained 167.7%, trading between 21.15 and 93.61.
Tweenvest scores Liquidia Corporation across four factors: quality 36/100, value 41/100, growth 100/100. Its strongest factor is growth.
LQDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.29B
- Revenue (TTM)
- $450.91M
- P/E
- 47.55
- EPS
- 1.48
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- $93.61
- 52-week low
- $21.15
- Avg volume (3M)
- —
- Shares outstanding
- 89.51M
- Employees
- 216
- Next earnings
- —
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
- ISIN
- US53635D2027
- Founded
- 2004
- Listed since
- Jul 26, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,262.11 | +1.22% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.40 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.45 | +2.52% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.60 | +0.86% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £123.85 | +2.27% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.42 | +1.61% |
Figures last refreshed Aug 18, 2026.